Posted by Michael Wonder on 16 Aug 2021
Lanadelumab in hereditary angioedema: added benefit not proven
16 August 2021 - The active ingredient has exceeded the sales limit for the simplified orphan drug assessment. There are no comparative studies. The analyses performed as a substitute are unsuitable for demonstrating an additional benefit.
The IQWiG, on behalf of the G-BA, investigated whether treatment with lanadelumab for the routine prophylaxis of recurrent attacks of hereditary angioedema offers patients 12 years and older an additional benefit compared to routine prophylaxis with C1 esterase inhibitor.
